Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy
Top Cited Papers
Open Access
- 25 September 2002
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 288 (12) , 1491-1498
- https://doi.org/10.1001/jama.288.12.1491
Abstract
As described previously,1 the Losartan Intervention For Endpoint reduction (LIFE) study was designed in the early 1990s when (1) reduction of cardiovascular (CV) morbidity and mortality with β-blocker- or diuretic-based antihypertensive therapy was suboptimal,2-5 (2) left ventricular hypertrophy (LVH) was a cardinal manifestation of preclinical CV disease and was a strong and independent risk factor for CV complications in hypertension, (3) indications that reversal of LVH was thought to have had prognostic benefit independent of blood pressure,6,7 (4) there was an association of angiotensin II with development of LVH, and (5) suggestive evidence that blocking angiotensin II was thought to be especially effective in reversing LVH and could confer protective benefits over and above blood pressure lowering.8Keywords
This publication has 23 references indexed in Scilit:
- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololPublished by Elsevier ,2002
- Angiotensin II Receptor Antagonists: An Emerging New Class of Cardiovascular Therapeutics.Hypertension Research, 1999
- Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertensionJournal Of Hypertension, 1998
- Association of change in left ventricular mass with prognosis during long-term antihypertensive treatmentJournal Of Hypertension, 1995
- Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension*American Journal of Hypertension, 1995
- Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy.Circulation, 1994
- Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the primary prevention trial in Goteborg, SwedenPublished by American Medical Association (AMA) ,1987
- Mortality in Patients of the Glasgow Blood Pressure ClinicJournal Of Hypertension, 1986
- High Risk of Cerebro‐cardiovascular Morbidity in Well Treated Male HypertensivesActa Medica Scandinavica, 1984
- Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham studyJAMA, 1981